Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Slides:

Advertisements

Similar presentations

RainDrop assay using 4 μL of genomic DNA Concentration of amplifiable DNA ≥ 50 ng? Copies/assay ≥ 10? T790M positive T790M negative reRainDrop assay using.

Advertisements

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor Tissue S. Das 1, L. Bazhenova 2, V. Singh 3, L. Arnold.

B Supplementary Figure S1A. Pre-amplification preserves mutant allele frequency and maintains sensitivity of ESR1-D538G mutation detection by ddPCR. A-B.

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

Big Data in Genomics, Diagnostics, and Precision Medicine

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Fig 1A. Patient enrollment flow chart

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Patient Case 1 Patient Case 1: PET/CT Scan.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

New Patient Journeys in Non-small cell lung cancer

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

S. E. Shackney, MD, C. A. Smith, A. Pollice, M. Levitt, MD, J. A

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Red: stable co-clustering Blue: no co-clustering

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients Antonio Marchetti, MD, PhD,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Technical advances in plasma genomic biomarkers

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases Yi-Lin Chen, Cheng-Chan Lu, Shu-Ching.

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

Detection rate for EGFR mutations in cfDNA.

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Representative CT and PET/CT images of three patients with NSCLCs

Figure 1. Plasma next-generation sequencing (NGS) assay workflow, comparison of variant allelic fraction with ... Figure 1. Plasma next-generation sequencing.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer Soyeon Kim, PhD, Tae Min Kim, MD, PhD,

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Chien-Wei Chen, MD, Chin-Wei Kuo, MD Journal of Thoracic Oncology

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

3p22.1 and 10q22.3 Deletions Detected by Fluorescence In Situ Hybridization (FISH): A Potential New Tool for Early Detection of Non-small Cell Lung Cancer.

MYD88 L265P + CCND3 I290R + QC2-03 QC2-05 QC2-11 QC2-12 QC2-13 QC2-19

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

Representative CT and PET/CT images of three patients with NSCLCs

Plasma and tissue EGFR allele analyses.

Mark I. Block, MD The Annals of Thoracic Surgery

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Detection of mutant alleles using ddPCR.

The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Presentation transcript:

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, Pajares MJ, Patiño-García A, Pio R, Lozano MD, Gúrpide A, Lopez-Picazo JM, Gil-Bazo I, Perez-Gracia JL, Gonzalez A Tumor Biology Corresponding author: Alvaro Gonzalez. Clinica Universidad de Navarra.

Supplementary Fig. 1: Schematic representation of patients and cfDNA samples included in the study Basal N=18 Best response N=13 Pre-progression N=7 Progression N=12 EGFR-TKI treatment 36 NSCLC patients with EGFR mutations detected in tissue biopsy 7 early stage NSCLC patients 29 advanced stage NSCLC patients 24 patients treated with EGFR-TKI 5 patients not treated with EGFR-TKI 5 basal samples 7 basal samples

Wild-type DNA for L858R mutation Positive cfDNA sample for L858R mutation Wild-type / HEX amplitude Mutant / FAM ampllitude Supplementary Fig. 2: 2-D Fluorescent amplitude plots for L858R (A), delE746-A750 (B) and T790M mutations corresponding to DNA from PBMC from a healthy control (above) and cfDNA from a NSCLC patient positive for the corresponding mutation (bottom). Black cluster on the plot corresponds to negative droplets, green cluster corresponds to droplets positive for wild type, blue cluster corresponds to droplets positive for the corresponding mutation, and orange cluster corresponds to droplets positive for both wild type and the corresponding mutation. Mutant / FAM ampllitude Wild-type / HEX amplitude Wild-type DNA for delE746-A750 mutation Positive cfDNA sample for delE746-A750 mutation Wild-type DNA for T790M mutation Positive cfDNA sample for T790M mutation Wild-type / HEX amplitude ABC

Supplementary Fig. 3: Correlation between EGFR mutated copies for L858R and delE746-A750 mutations and mutated copies for T790M mutation, in cfDNA from samples positive for EGFR mutations.